Next Article in Journal
Newly Diagnosed Multifocal GBM: A Monocentric Experience and Literature Review
Next Article in Special Issue
Outcomes of Intercalary Endoprostheses as a Treatment for Metastases in the Femoral and Humeral Diaphysis
Previous Article in Journal
STR Profiling Reveals Tumor Genome Instability in Primary Mediastinal B-Cell Lymphoma
Previous Article in Special Issue
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw
Article

Megaprosthesis for Metastatic Bone Disease—A Comparative Analysis

1
Division of Orthopaedic Surgery, Oslo University Hospital, 0424 Oslo, Norway
2
Faculty of Law, University of Oslo, 0315 Oslo, Norway
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2022, 29(5), 3460-3471; https://doi.org/10.3390/curroncol29050279
Received: 8 April 2022 / Revised: 25 April 2022 / Accepted: 6 May 2022 / Published: 10 May 2022
(This article belongs to the Special Issue Treatment of Bone Metastasis)
Background: Megaprosthetic reconstruction is sometimes indicated in advanced metastatic bone disease (MBD) of the appendicular skeleton with large degrees of bone loss or need for oncological segmental resection. Outcome after megaprosthetic reconstruction was studied in the setting of primary bone sarcoma with high levels of complications, but it is not known if this applies to MBD. Method: We performed a comparative analysis of complications and revision surgery for MBD and bone sarcoma surgery in an institutional cohort from 2005–2019. Presented are the descriptive data of the cohort, with Kaplan–Meier (K–M) rates of revision at 1, 2 and 5 years together with a competing risk analysis by indication type. Results: Rates of revision surgery are significantly lower for MBD (8% at 1 year, 12% at 2 years), in the intermediate term, compared to that of sarcoma (18% at 1 year, 24% at 2 years) (p = 0.04). At 5 years this is not significant by K–M analysis (25% for MBD, and 33% for sarcoma), but remains significant in a competing risk model (8% for MBD, and 20% for sarcoma) (p = 0.03), accounting for death as a competing event. Conclusion: Rates of revision surgery after megaprosthetic reconstruction of MBD are significantly lower than that for primary bone sarcoma in this cohort. View Full-Text
Keywords: megaprosthesis; metastatic bone disease; surgery; complications; revision; sarcoma megaprosthesis; metastatic bone disease; surgery; complications; revision; sarcoma
Show Figures

Figure 1

MDPI and ACS Style

Thorkildsen, J.; Strøm, T.A.; Strøm, N.J.; Sellevold, S.; Norum, O.-J. Megaprosthesis for Metastatic Bone Disease—A Comparative Analysis. Curr. Oncol. 2022, 29, 3460-3471. https://doi.org/10.3390/curroncol29050279

AMA Style

Thorkildsen J, Strøm TA, Strøm NJ, Sellevold S, Norum O-J. Megaprosthesis for Metastatic Bone Disease—A Comparative Analysis. Current Oncology. 2022; 29(5):3460-3471. https://doi.org/10.3390/curroncol29050279

Chicago/Turabian Style

Thorkildsen, Joachim, Thale A. Strøm, Nils J. Strøm, Simen Sellevold, and Ole-Jacob Norum. 2022. "Megaprosthesis for Metastatic Bone Disease—A Comparative Analysis" Current Oncology 29, no. 5: 3460-3471. https://doi.org/10.3390/curroncol29050279

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop